Newcells Biotech, a UK-based stem cell technology spinout from Newcastle University, has raised £2m ($2.6m) in funding from Northstar Ventures and NVM Private Equity.
Founded in 2015, Newcells Biotech develops assays for pre-clinical disease and drug safety based on human-induced pluripotent stem cells (hiPSC), which can be used to grow several different types of cell.
The approach is intended to give researchers more physiologically accurate 2D and 3D in vivo assays.
Newcells has so far launched two hiPSC-based assays for the kidney,…
